In short
ATL001 is an innovative personalized therapy currently being tested in clinical trials for patients with advanced non-small cell lung cancer (NSCLC) and metastatic or recurrent melanoma. This treatment uses the patient's own T cells, which are modified to target specific mutations found in their cancer cells. The trials aim to evaluate the safety and effectiveness of ATL001 when used alone or in combination with other immunotherapy drugs.
At a glance
- Treatment
- ATL001 (personalized T cell therapy)
- Conditions studied
- Advanced non-small cell lung cancer (NSCLC), Metastatic or recurrent melanoma
- Trial phase
- Phase I/IIa
- Administration
- Intravenous infusion
- Combination therapies
- Pembrolizumab (for NSCLC), Nivolumab (for melanoma)
- Primary objective
- Assess safety and tolerability
- Secondary objectives
- Evaluate clinical efficacy (tumor size changes, response rates, survival outcomes)
- Key eligibility criteria
- Adults with advanced disease, prior treatment with PD-1/PD-L1 inhibitor, adequate organ function
- Main exclusion criteria
- Untreated brain metastases, active autoimmune diseases, recent live vaccinations
What is ATL001?
ATL001 is an innovative personalized therapy being developed to treat advanced cancers. It belongs to a category of treatments called Advanced Therapy Medicinal Products (ATMPs), specifically a type of cell therapy. This means ATL001 uses living cells as part of the treatment.
How ATL001 Works
ATL001 is a type of therapy called neoantigen reactive T cells. Here's a simplified explanation of how it works:
- The treatment is personalized for each patient.
- It targets specific mutations (changes in DNA) that are found in all of a patient's cancer cells.
- T cells (a type of immune cell) are taken from the patient's body.
- These T cells are modified to recognize and attack the patient's specific cancer mutations.
- The modified T cells (ATL001) are then given back to the patient to fight the cancer.
Target Conditions
ATL001 is being studied for two main types of advanced cancers:
- Non-small cell lung cancer (NSCLC): This is a type of lung cancer that has spread to other parts of the body or has come back after previous treatment.
- Metastatic or recurrent melanoma: This is a type of skin cancer that has spread to other parts of the body or has come back after previous treatment.
Clinical Trials
ATL001 is currently being tested in clinical trials. These trials are designed to:
- Assess how safe ATL001 is for patients.
- Determine how well patients tolerate the treatment.
- Evaluate how effective ATL001 is at treating cancer.
The trials are testing ATL001 both as a standalone treatment and in combination with other cancer drugs called pembrolizumab (for lung cancer) or nivolumab (for melanoma).
Administration
ATL001 is given to patients through an intravenous infusion. This means it's delivered directly into the bloodstream through a vein. Before receiving ATL001, patients typically undergo a process called lymphodepletion, which helps prepare their body for the treatment.
Potential Benefits
While ATL001 is still being studied, researchers hope it may offer several potential benefits:
- Personalized treatment targeting each patient's specific cancer.
- Potential to treat cancers that have not responded to other therapies.
- Possible improvement in tumor size and overall survival.
Safety Considerations
As with any new treatment, there are potential risks and side effects. The clinical trials are carefully monitoring patients for:
- Adverse events (side effects) related to ATL001 and other drugs used in the treatment process.
- How well patients tolerate the treatment.
- Any serious side effects that may occur.
It's important to note that ATL001 is still an experimental treatment. More research is needed to fully understand its effectiveness and safety profile. Patients interested in this treatment should discuss it with their healthcare provider to determine if it might be appropriate for their specific situation.